BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cuypers L, Li G, Libin P, Piampongsant S, Vandamme AM, Theys K. Genetic Diversity and Selective Pressure in Hepatitis C Virus Genotypes 1-6: Significance for Direct-Acting Antiviral Treatment and Drug Resistance. Viruses 2015;7:5018-39. [PMID: 26389941 DOI: 10.3390/v7092857] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 6.9] [Reference Citation Analysis]
Number Citing Articles
1 Rossetti B, Bai F, Tavelli A, Galli M, Antinori A, Castelli F, Pellizzer G, Cozzi-Lepri A, Bonora S, Monforte AD, Puoti M, De Luca A; ICONA Foundation study group. Evolution of the prevalence of hepatitis C virus infection and hepatitis C virus genotype distribution in human immunodeficiency virus-infected patients in Italy between 1997 and 2015. Clin Microbiol Infect 2018;24:422-7. [PMID: 28765078 DOI: 10.1016/j.cmi.2017.07.021] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
2 Cuypers L, Libin P, Schrooten Y, Theys K, Di Maio VC, Cento V, Lunar MM, Nevens F, Poljak M, Ceccherini-Silberstein F, Nowé A, Van Laethem K, Vandamme AM. Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning. Infect Genet Evol 2017;53:15-23. [PMID: 28499845 DOI: 10.1016/j.meegid.2017.05.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
3 Roger S, Ducancelle A, Le Guillou-Guillemette H, Gaudy C, Lunel F. HCV virology and diagnosis. Clin Res Hepatol Gastroenterol 2021;45:101626. [PMID: 33636428 DOI: 10.1016/j.clinre.2021.101626] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
4 Marascio N, Costantino A, Taffon S, Lo Presti A, Equestre M, Bruni R, Pisani G, Barreca GS, Quirino A, Trecarichi EM, Costa C, Mazzitelli M, Serapide F, Matera G, Torti C, Liberto MC, Ciccaglione AR. Phylogenetic and Molecular Analyses of More Prevalent HCV1b Subtype in the Calabria Region, Southern Italy. J Clin Med 2021;10:1655. [PMID: 33924449 DOI: 10.3390/jcm10081655] [Reference Citation Analysis]
5 Trucchi C, Orsi A, Alicino C, Sticchi L, Icardi G, Ansaldi F. State of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and Immunization. J Immunol Res 2016;2016:1412840. [PMID: 27843956 DOI: 10.1155/2016/1412840] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
6 Zhang J, Zhang S, Zuo L, Yue W, Li S, Xin S, Liu L, Lu J. Differential expression profiling of lncRNAs related to Epstein‐Barr virus infection in the epithelial cells. J Med Virol 2019;91:1845-55. [DOI: 10.1002/jmv.25516] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
7 Aguiar BF, Campos GRF, Rodrigues JPV, Marques NN, Molina BF, Bittar C, Souza FF, Martinelli ALC, Rahal P, Pereira LRL. Baseline resistance associated substitutions in HCV genotype 1 infected cohort treated with Simeprevir, Daclatasvir and Sofosbuvir in Brazil. Clin Res Hepatol Gastroenterol 2020;44:329-39. [PMID: 31523019 DOI: 10.1016/j.clinre.2019.07.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
8 Cuypers L, Ceccherini-Silberstein F, Van Laethem K, Li G, Vandamme AM, Rockstroh JK. Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time. Rev Med Virol 2016;26:408-34. [PMID: 27401933 DOI: 10.1002/rmv.1895] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
9 Mesbahi Z, Kabbaj H, Malki H, Bouihat N, Qrafli M, Belefquih B, Marcil S, Challine D, Pawlotsky JM, Bouvier M, Seffar M. Indeterminate genotypes of hepatitis C virus by the Abbott RealTime HCV Genotype II assay in Morocco. About eight cases resolved by a sequencing method. J Med Virol 2018;90:1352-7. [PMID: 29663433 DOI: 10.1002/jmv.25191] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Xu R, Wang H, Huang J, Wang M, Liao Q, Shan Z, Zhong H, Rong X, Fu Y. Complete genome sequencing and evolutionary analysis of hepatitis C virus subtype 6a, including strains from Guangdong Province, China. Arch Virol 2022. [PMID: 35050401 DOI: 10.1007/s00705-021-05358-7] [Reference Citation Analysis]
11 Hasanshahi Z, Hashempour A, Ghasabi F, Moayedi J, Musavi Z, Dehghani B, Sharafi H, Joulaei H. First report on molecular docking analysis and drug resistance substitutions to approved HCV NS5A and NS5B inhibitors amongst Iranian patients. BMC Gastroenterol 2021;21:443. [PMID: 34819046 DOI: 10.1186/s12876-021-01988-y] [Reference Citation Analysis]
12 Parczewski M, Cielniak I, Kordek J, Aksak-wąs B, Urbańska A, Leszczyszyn-pynka M, Siwak E, Bociąga-jasik M, Nowak A, Szymczak A, Zalewska M, Łojewski W, Vandamme A, Lübke N, Cuypers L. Transmission Networks of HCV Genotype 1a Enriched With Pre-existing Polymorphism Q80K Among HIV-Infected Patients With Acute Hepatitis C in Poland. JAIDS Journal of Acquired Immune Deficiency Syndromes 2018;77:514-22. [DOI: 10.1097/qai.0000000000001628] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
13 Morsica G, Andolina A, Merli M, Messina E, Hasson H, Lazzarin A, Uberti-Foppa C, Bagaglio S. NS3 protease resistance-associated substitutions in liver tissue and plasma samples from patients infected by hepatitis C virus genotype 1A or 1B. Arch Virol 2017;162:2271-7. [PMID: 28421367 DOI: 10.1007/s00705-017-3341-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
14 Bhardwaj N, Ragonnet-Cronin M, Murrell B, Chodavarapu K, Martin R, Chang S, Miller MD, Feld JJ, Sulkowski M, Mangia A, Wertheim JO, Osinusi A, McNally J, Brainard D, Mo H, Svarovskaia ES. Intrapatient viral diversity and treatment outcome in patients with genotype 3a hepatitis C virus infection on sofosbuvir-containing regimens. J Viral Hepat 2018;25:344-53. [PMID: 29112331 DOI: 10.1111/jvh.12825] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
15 Nováková L, Pavlík J, Chrenková L, Martinec O, Červený L. Current antiviral drugs and their analysis in biological materials - Part II: Antivirals against hepatitis and HIV viruses. J Pharm Biomed Anal 2018;147:378-99. [PMID: 29031512 DOI: 10.1016/j.jpba.2017.07.003] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 5.2] [Reference Citation Analysis]
16 Qi M, Yang M, Xu L, Ma C, Huang P, Sun J, Shi J, Hu Y. Complete genome analysis identifies recombinant events and positive selection sites of hepatitis C virus from mainland China during 2010-2019. Virus Res 2021;296:198354. [PMID: 33639223 DOI: 10.1016/j.virusres.2021.198354] [Reference Citation Analysis]
17 Cuypers L, Li G, Neumann-Haefelin C, Piampongsant S, Libin P, Van Laethem K, Vandamme AM, Theys K. Mapping the genomic diversity of HCV subtypes 1a and 1b: Implications of structural and immunological constraints for vaccine and drug development. Virus Evol 2016;2:vew024. [PMID: 27774307 DOI: 10.1093/ve/vew024] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
18 Mirian M, Khanahmad H, Darzi L, Salehi M, Sadeghi-Aliabadi H. Oligonucleotide aptamers: potential novel molecules against viral hepatitis. Res Pharm Sci 2017;12:88-98. [PMID: 28515761 DOI: 10.4103/1735-5362.202447] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
19 Stelzl E, Haas B, Bauer B, Zhang S, Fiss EH, Hillman G, Hamilton AT, Mehta R, Heil ML, Marins EG, Santner BI, Kessler HH. First identification of a recombinant form of hepatitis C virus in Austrian patients by full-genome next generation sequencing. PLoS One 2017;12:e0181273. [PMID: 28742818 DOI: 10.1371/journal.pone.0181273] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
20 Parra M, Laufer N, Manrique JM, Jones LR, Quarleri J. Phylogenetic Diversity in Core Region of Hepatitis C Virus Genotype 1a as a Factor Associated with Fibrosis Severity in HIV-1-Coinfected Patients. Biomed Res Int 2017;2017:1728456. [PMID: 29259976 DOI: 10.1155/2017/1728456] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
21 Cuypers L, Thijssen M, Shakibzadeh A, Sabahi F, Ravanshad M, Pourkarim MR. Next-generation sequencing for the clinical management of hepatitis C virus infections: does one test fits all purposes? Crit Rev Clin Lab Sci 2019;56:420-34. [PMID: 31317801 DOI: 10.1080/10408363.2019.1637394] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
22 Marascio N, Pavia G, Strazzulla A, Dierckx T, Cuypers L, Vrancken B, Barreca GS, Mirante T, Malanga D, Oliveira DM, Vandamme AM, Torti C, Liberto MC, Focà A; The SINERGIE-UMG Study Group. Detection of Natural Resistance-Associated Substitutions by Ion Semiconductor Technology in HCV1b Positive, Direct-Acting Antiviral Agents-Naïve Patients. Int J Mol Sci 2016;17:E1416. [PMID: 27618896 DOI: 10.3390/ijms17091416] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
23 Bhattacharjee C, Nandy SK, Das P, Mukhopadhyay A. Differential interaction strategies of hepatitis c virus genotypes during entry - An in silico investigation of envelope glycoprotein E2 - CD81 interaction. Infect Genet Evol 2019;69:48-60. [PMID: 30639544 DOI: 10.1016/j.meegid.2019.01.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
24 Gao R, Zu W, Liu Y, Li J, Li Z, Wen Y, Wang H, Yuan J, Cheng L, Zhang S, Zhang Y, Zhang S, Liu W, Lan X, Liu L, Li F, Zhang Z. Quasispecies of SARS-CoV-2 revealed by single nucleotide polymorphisms (SNPs) analysis. Virulence 2021;12:1209-26. [PMID: 34030593 DOI: 10.1080/21505594.2021.1911477] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Li G, De Clercq E. Current therapy for chronic hepatitis C: The role of direct-acting antivirals. Antiviral Res. 2017;142:83-122. [PMID: 28238877 DOI: 10.1016/j.antiviral.2017.02.014] [Cited by in Crossref: 93] [Cited by in F6Publishing: 83] [Article Influence: 18.6] [Reference Citation Analysis]
26 Tsyvina V, Campo DS, Sims S, Zelikovsky A, Khudyakov Y, Skums P. Fast estimation of genetic relatedness between members of heterogeneous populations of closely related genomic variants. BMC Bioinformatics 2018;19:360. [PMID: 30343669 DOI: 10.1186/s12859-018-2333-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
27 Caporossi A, Kulkarni O, Blum M, Leroy V, Morand P, Larrat S, François O. Using high-throughput sequencing for investigating intra-host hepatitis C evolution over long retrospective periods. Infect Genet Evol 2019;67:136-44. [PMID: 30395998 DOI: 10.1016/j.meegid.2018.11.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
28 Cuypers L, Snoeck J, Kerremans L, Libin P, Crabbé R, Van Dooren S, Vuagniaux G, Vandamme AM. HCV1b genome evolution under selective pressure of the cyclophilin inhibitor alisporivir during the DEB-025-HCV-203 phase II clinical trial. Infect Genet Evol 2016;44:169-81. [PMID: 27374748 DOI: 10.1016/j.meegid.2016.06.050] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
29 Gane E, Poordad F, Wang S, Asatryan A, Kwo PY, Lalezari J, Wyles DL, Hassanein T, Aguilar H, Maliakkal B, Liu R, Lin CW, Ng TI, Kort J, Mensa FJ. High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis. Gastroenterology 2016;151:651-659.e1. [PMID: 27456384 DOI: 10.1053/j.gastro.2016.07.020] [Cited by in Crossref: 72] [Cited by in F6Publishing: 69] [Article Influence: 12.0] [Reference Citation Analysis]
30 Sevvana M, Keck Z, Foung SK, Kuhn RJ. Structural perspectives on HCV humoral immune evasion mechanisms. Curr Opin Virol 2021;49:92-101. [PMID: 34091143 DOI: 10.1016/j.coviro.2021.05.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
31 Harms D, Wang B, Papp CP, Bock CT. Capturing virus evolution by proteomic bioinformatics: Hunting for characteristic mutations in the hepatitis E virus genome. Virulence 2018;9:13-6. [PMID: 28945510 DOI: 10.1080/21505594.2017.1384526] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
32 Cuypers L, Thijssen M, Shakibzadeh A, Deboutte W, Sarvari J, Sabahi F, Ravanshad M, Pourkarim MR. Signature of natural resistance in NS3 protease revealed by deep sequencing of HCV strains circulating in Iran. Infect Genet Evol 2019;75:103966. [PMID: 31323326 DOI: 10.1016/j.meegid.2019.103966] [Reference Citation Analysis]
33 Esposito I, Trinks J, Soriano V. Hepatitis C virus resistance to the new direct-acting antivirals. Expert Opin Drug Metab Toxicol. 2016;12:1197-1209. [PMID: 27384079 DOI: 10.1080/17425255.2016.1209484] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 5.7] [Reference Citation Analysis]
34 Kumar A, Pandey R, Yadav IS, Bharadwaj M. Structural and Epitope Analysis (T- and B-Cell Epitopes) of Hepatitis C Virus (HCV) Glycoproteins: An in silico Approach. J Clin Exp Hepatol 2018;8:352-61. [PMID: 30568344 DOI: 10.1016/j.jceh.2017.12.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
35 Abdel-Hameed EA, Rouster SD, Zhang X, Chen J, Medvedovic M, Goodman ZD, Sherman KE. Characterization of HCV NS3 Protease Variants in HCV/HIV-Coinfected Patients by Ultra-Deep Sequence Analysis: Relationship with Hepatic Fibrosis. J Acquir Immune Defic Syndr 2017;74:353-8. [PMID: 27898525 DOI: 10.1097/QAI.0000000000001256] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
36 Kletenkov K, Hoffmann D, Böni J, Yerly S, Aubert V, Schöni-Affolter F, Struck D, Verheyen J, Klimkait T; Swiss HIV Cohort Study. Role of Gag mutations in PI resistance in the Swiss HIV cohort study: bystanders or contributors? J Antimicrob Chemother 2017;72:866-75. [PMID: 27999036 DOI: 10.1093/jac/dkw493] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
37 Romeo I, Marascio N, Pavia G, Talarico C, Costa G, Alcaro S, Artese A, Torti C, Liberto MC, Focà A. Structural Modeling of New Polymorphism Clusters of HCV Polymerase Isolated from Direct‐Acting Antiviral Naïve Patients: Focus on Dasabuvir and Setrobuvir Binding Affinity. ChemistrySelect 2018;3:6009-17. [DOI: 10.1002/slct.201800649] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
38 Zeng H, Li L, Hou Z, Zhang Y, Tang Z, Liu S. Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges. Int J Med Sci. 2020;17:892-902. [PMID: 32308542 DOI: 10.7150/ijms.43079] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
39 Coppola N, Minichini C, Starace M, Sagnelli C, Sagnelli E. Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals: HCV Mutations Versus DAAs. J Med Virol 2016;88:1659-71. [DOI: 10.1002/jmv.24527] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
40 Cuypers L, Vrancken B, Fabeni L, Marascio N, Cento V, Di Maio VC, Aragri M, Pineda-Peña AC, Schrooten Y, Van Laethem K, Balog D, Focà A, Torti C, Nevens F, Perno CF, Vandamme AM, Ceccherini-Silberstein F. Implications of hepatitis C virus subtype 1a migration patterns for virus genetic sequencing policies in Italy. BMC Evol Biol 2017;17:70. [PMID: 28270091 DOI: 10.1186/s12862-017-0913-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
41 Iwamoto M, Calzia A, Dublineau A, Rouet F, Nouhin J, Yann S, Pin S, Sun C, Sann K, Dimanche C, Lastrucci C, Coulborn RM, Maman D, Dousset JP, Loarec A. Field evaluation of GeneXpert® (Cepheid) HCV performance for RNA quantification in a genotype 1 and 6 predominant patient population in Cambodia. J Viral Hepat 2019;26:38-47. [PMID: 30199587 DOI: 10.1111/jvh.13002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
42 Aldunate F, Echeverría N, Chiodi D, López P, Sánchez-Cicerón A, Fajardo A, Soñora M, Cristina J, Hernández N, Moreno P. Pretreatment Hepatitis C Virus NS5A/NS5B Resistance-Associated Substitutions in Genotype 1 Uruguayan Infected Patients. Dis Markers 2018;2018:2514901. [PMID: 30186532 DOI: 10.1155/2018/2514901] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
43 Ndjoyi-Mbiguino A, Kombe Kombe AJ, Bivigou-Mboumba B, Zoa-Assoumou S, Akombi FL, Nzengui Nzengui F, M'boyis Kamdem H, François-Souquière S. Low prevalence of HCV infection with predominance of genotype 4 among HIV patients living in Libreville, Gabon. PLoS One 2018;13:e0190529. [PMID: 29385148 DOI: 10.1371/journal.pone.0190529] [Reference Citation Analysis]
44 De Clercq E, Li G. Approved Antiviral Drugs over the Past 50 Years. Clin Microbiol Rev. 2016;29:695-747. [PMID: 27281742 DOI: 10.1128/cmr.00102-15] [Cited by in Crossref: 592] [Cited by in F6Publishing: 276] [Article Influence: 98.7] [Reference Citation Analysis]
45 Torres-vázquez B, María de Lucas A, García-crespo C, Antonio García-martín J, Fragoso A, Fernández-algar M, Perales C, Domingo E, Moreno M, Briones C. In vitro selection of high affinity DNA and RNA aptamers that detect hepatitis C virus core protein of genotypes 1 to 4 and inhibit virus production in cell culture. Journal of Molecular Biology 2022. [DOI: 10.1016/j.jmb.2022.167501] [Reference Citation Analysis]
46 Miao M, Jing X, De Clercq E, Li G. Danoprevir for the Treatment of Hepatitis C Virus Infection: Design, Development, and Place in Therapy. Drug Des Devel Ther 2020;14:2759-74. [PMID: 32764876 DOI: 10.2147/DDDT.S254754] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
47 Marascio N, Mazzitelli M, Pavia G, Giancotti A, Barreca GS, Costa C, Pisani V, Greco G, Serapide F, Trecarichi EM, Casalinuovo F, Liberto MC, Matera G, Torti C. Clinical, Virological Characteristics, and Outcomes of Treatment with Sofosbuvir/Ledipasvir in Two Pediatric Patients Infected by HCV Genotype 4. Cells. 2019;8. [PMID: 31060315 DOI: 10.3390/cells8050416] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
48 Theys K, Libin PJK, Van Laethem K, Abecasis AB. An Evolutionary Model-Based Approach To Quantify the Genetic Barrier to Drug Resistance in Fast-Evolving Viruses and Its Application to HIV-1 Subtypes and Integrase Inhibitors. Antimicrob Agents Chemother 2019;63:e00539-19. [PMID: 31109980 DOI: 10.1128/AAC.00539-19] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]